|
|
Article: CollaGenex Pharmaceuticals Reports Statistically and Clinically Significant Results from Dermostat Acne Study.
- Article from:
- Business Wire
- Article date:
- October 1, 2001
CopyrightCOPYRIGHT 2001 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors
NEWTOWN, Pa.--(BUSINESS WIRE)--Oct. 1, 2001
- New Therapeutic Approach Resulted in More Than a 50% Reduction in
Both Comedones and Inflammatory Lesions -
CollaGenex Pharmaceuticals, Inc. (Nasdaq:CGPI) today announced the clinically and statistically significant results of a six-month, 60-patient clinical trial designed to evaluate the efficacy of Dermostat, a sub-antimicrobial regimen of doxycycline hyclate tablets, 20 mg, for the treatment of patients with moderate acne.
The results showed that the patients receiving Dermostat experienced more than a 50% reduction in comedones and inflammatory lesions. Patent ...
Related newspaper, magazine, and journal articles:
|
|
Article: Collagenex Pharmaceuticals to Collaborate With ...
PR Newswire;
November 5, 1997 ;
700+ words
... ... Nov. 5 /PRNewswire/ -- CollaGenex Pharmaceuticals, Inc. (Nasdaq: CGPI) today ... in companion animal health." CollaGenex Pharmaceuticals, Inc. is engaged in the development ... commercially successful. SOURCE CollaGenex Pharmaceuticals, Inc. -0- 11/05/97 ...
|
|